Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
OPK · Nasdaq · United States · Pharmaceutical Preparations
In shortOPKO HEALTH, INC. is loss-making, burns cash and holds more cash than debt, with revenue shrinking (−14.9% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -19.3% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -37.2% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -17.1% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -8.6% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 3.97× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.00× | 100/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -0.79 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -31.4% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 1 of 5 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 0 of 5 | 0/100 |
|---|---|---|
| Years of revenue decline (last 5) | 4 of 5 | 0/100 |
| Revenue growth volatility | 23.9% | 22/100 |
| Operating margin volatility | 9.7% | 21/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | -15.5% | 0/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 1,775 | 1,004 | 863 | 713 | 607 |
| Cost of revenue | – | 716 | 545 | 495 | 401 |
| Gross profit | – | 288 | 318 | 219 | 206 |
| Research & development | 77 | 74 | 90 | 105 | 124 |
| Selling, general & admin | 469 | 373 | 301 | 304 | 223 |
| Operating income | 19 | (226) | (157) | (152) | (117) |
| Interest expense | 19 | 12 | 14 | 47 | 0 |
| Pre-tax income | (14) | (392) | (184) | (10) | (241) |
| Income tax | 15 | (63) | 4.4 | 43 | (16) |
| Net income | (30) | (328) | (189) | (53) | (226) |
| Diluted EPS | −$0.05 | −$0.46 | −$0.25 | −$0.08 | −$0.30 |
| Diluted shares (millions) | 648 | 719 | 752 | 694 | 751 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
−0.79 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
4/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 28, 2026